Results 61 to 70 of about 85,967 (221)

From Genomic and Epigenomic Maps to Medicines in Adult T‐Cell Leukemia/Lymphoma

Cancer Science, Volume 117, Issue 2, Page 289-296, February 2026.
ABSTRACT Adult T‐cell leukemia/lymphoma (ATL) is an aggressive and refractory hematologic malignancy that is caused by human T‐cell leukemia virus type‐1 (HTLV‐1) retrovirus. ATL results from a combination of viral latency and the accumulation of abnormalities throughout the genome, epigenome, transcriptome, and signaling pathways.
Kako Suzuki, Makoto Yamagishi
wiley   +1 more source

Evaluation serum soluble interleukin 2 receptor with diagnosis and prognosis in canine solid tumour: 34 cases

Veterinary Medicine and Science
Background/Aim The soluble interleukin‐2 receptor (sIL‐2R) serve as a valuable biomarker for tumors in human patients, as its levels increase during the activation of T lymphocytes in clinical states such as inflammation, infection, and tumor. This study
Hyun NamKung, Su‐Min Park, Jae‐Hyeon Im, Ga‐Hyun Lim, Min‐Ok Ryu, Kyoung‐Won Seo, Hwa‐Young Youn   +6 more
doaj   +1 more source

Ischemic Stroke in Hypereosinophilic Syndrome: A Clinicopathologic Study of Two Cases

Neuropathology, Volume 46, Issue 1, February 2026.
ABSTRACT Ischemic stroke is a rare complication of hypereosinophilic syndrome (HES). Manifestations of stroke in HES have been described in the radiologic literature; however the pathologic characterization of central nervous system (CNS) involvement in HES is limited.
Karina C. Martin, Dan Straathof, Chi Lai, Harry V. Vinters   +3 more
wiley   +1 more source

The importance of interleukin-2 and its soluble receptor in patients with multiple sclerosis and other inflammatory diseases of the central nervous system [PDF]

, 1992
Interleukin-2 (IL-2) was originally identified in 1976 as a growth factor for T lymphocytes. Since that time it has become an important mediator of immune functions through its effects on the growth, development, and activity of T and B lymphocytes ...
Sharief, Mohammad Kassim
core  

Real‐World Outcomes of Polatuzumab Vedotin Plus R‐CHP Versus R‐CHOP‐Based Regimens in Japanese Patients With Untreated Diffuse Large B‐Cell Lymphoma

Cancer Medicine, Volume 15, Issue 1, January 2026.
PV‐R‐CHP showed improved progression‐free and overall survivals compared to R‐CHOP‐based regimens in newly diagnosed Japanese patients with DLBCL, particularly in those with non‐GCB subtype. These results were consistent in both the overall cohort and propensity score‐matched cohorts.
Masaaki Hotta, Atsushi Satake, Ayako Iwama, Tokiko Hoshiyama, Yukie Tsubokura, Hideaki Yoshimura, Shinya Fujita, Yumiko Kono, Tomoki Ito   +8 more
wiley   +1 more source

Early IL-2/sIL-2R surge following surgery leads to temporary immune refractoriness [PDF]

Clinical and Experimental Immunology, 1993
SUMMARYHigh serum level of immunoreactive but not biologically active IL-2 was detected 1 day after surgery in patients undergoing major operation (abdominal, open-heart), in proportion to the tissue injury caused by surgical trauma. IL-2 values were highest in those patients who underwent open-heart surgery and received blood transfusions.
N, Lahat, R, Shtiller, A Y, Zlotnick, G, Merin   +3 more
openaire   +2 more sources

Managing Treatment‐Emergent Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CAR‐T Cell Therapy: A Case‐Based Review of the use of Emapalumab

Hematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapies have revolutionized the treatment of hematological malignancies, achieving high response rates in patients with relapsed or refractory disease. Despite these benefits, CAR‐T cell therapies are associated with unique toxicities, including cytokine release syndrome (CRS), immune effector cell ...
Livia Donzelli, Veronica Zullino, Giovanni Fernando Torelli, Maria Stefania De Propris, Mario Piazzolla, Franco Ruberto, Maurizio Martelli, Alice Di Rocco   +7 more
wiley   +1 more source

Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH

Blood Advances, 2017
: Serum soluble interleukin-2 receptor (sIL-2r) is an important disease marker in hemophagocytic lymphohistiocytosis (HLH), but there are no published data on its diagnostic value in adults.
Anna Hayden, Molly Lin, Sujin Park, Morris Pudek, Marion Schneider, Michael B. Jordan, Andre Mattman, Luke Y.C. Chen   +7 more
doaj   +1 more source

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

Hematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT The optimal second‐line chemotherapy regimen for relapsed or refractory diffuse large B‐cell lymphoma (R/R DLBCL) remains uncertain. We retrospectively compared efficacy and safety between gemcitabine, carboplatin, dexamethasone, and rituximab (GCD‐R) and cyclophosphamide, high‐dose cytarabine, dexamethasone, etoposide, and rituximab (CHASER ...
Yoshikazu Ikoma, Nobuhiko Nakamura, Junichi Kitagawa, Naoki Hayase, Eri Takada, Takuro Matsumoto, Yuhei Shibata, Hiroshi Nakamura, Kei Fujita, Shin Lee, Tetsuji Morishita, Nobuhiro Kanemura, Senji Kasahara, Hideko Goto, Kenji Fukuno, Takeshi Hara, Michio Sawada, Hisashi Tsurumi, Masahito Shimizu   +18 more
wiley   +1 more source

Pheochromocytoma and Diffuse Large B‐Cell Lymphoma in the Ipsilateral Adrenal Gland: A Case Report

IJU Case Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Introduction Pheochromocytoma is a catecholamine‐producing tumor arising from the adrenal medulla. When it coexists with a tumor of different origin within the same adrenal gland, it is classified as a collision tumor involving a pheochromocytoma.
Ken Maekawa, Toru Sakatani, Yuki Kita, Kimihiko Masui, Takayuki Goto, Yuki Teramoto, Taisuke Hosokai, Ichiro Yamauchi, Sho Koyasu, Takashi Kobayashi   +9 more
wiley   +1 more source